Archives
-
Phosphatase Inhibitor Cocktail 2: Assay Workflows
2026-08-14
Preserve labile phosphorylation states from lysis through Western blotting, co-immunoprecipitation, kinase assays, and tissue workflows with a ready-to-dilute broad-spectrum inhibitor mix. A low-temperature, rationally simplified strategy inspired by recent DT-TRAP findings helps reduce sample variability while keeping phosphoprotein experiments practical.
-
Carbapenemase Gene Transfer in CREC, 2022–2024
2026-08-13
Chen et al. provide a multicenter analysis of carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong teaching hospitals. The study combines gene localization, antimicrobial susceptibility testing, conjugation, mobile-element profiling, and ERIC-PCR to show that plasmid-associated blaNDM-1 and highly transferable resistance determinants contribute to both horizontal spread and likely clonal dissemination.
-
2-Deoxy-D-glucose: Glycolysis Research Workflows
2026-08-13
Build reproducible cancer, antiviral, and immunometabolism assays with 2-Deoxy-D-glucose, from stock preparation through cytokine and viability readouts. The guide combines practical 2-DG workflows with whole-blood stimulation, model-specific controls, and troubleshooting for separating metabolic regulation from nonspecific toxicity.
-
Verteporfin (CL 318952) Research Workflows
2026-08-12
Verteporfin combines light-gated phototoxicity with light-independent modulation of autophagy, making it useful for matched mechanistic assays rather than single-endpoint screens. This guide translates its product specifications and senescence-screening insights into practical workflows for ocular, cancer, and cell-death research.
-
SB 431542: ALK5 Inhibitor Workflow Guide
2026-08-12
Use SB 431542 to separate TGF-β-driven Smad2 signaling from downstream changes in proliferation, invasion, and epithelial-to-mesenchymal transition. This workflow guide connects pathway validation in endometriosis models with practical assay design for glioma and anti-tumor immunology research.
-
ACE2 Activation in Sepsis Cardiomyopathy
2026-08-11
The February 2024 study in Archives of Biochemistry and Biophysics identifies ACE2 downregulation as a feature of sepsis-induced cardiomyopathy and examines whether pharmacological ACE2 activation can restore cardiac function. Using Diminazene Aceturate and the ACE2 inhibitor MLN-4760 in a mouse cecal ligation and puncture model, the authors connect ACE2–MasR–Sirt1 signaling with mitochondrial biogenesis, inflammation, oxidative stress, and cardiomyocyte apoptosis.
-
Sulfamonomethoxine: From Mechanism to Assay Design
2026-08-11
Sulfamonomethoxine and SMM connect DHPS inhibition with practical veterinary, aquaculture, and ecotoxicology workflows. This evidence-led guide shows how trophic-level sensitivity, solvent choice, and environmental transformation should shape assay design.
-
Prochlorperazine-Induced Neuroleptic Malignant Syndrome
2026-08-10
This case report describes neuroleptic malignant syndrome after two weeks of standard-dose prochlorperazine in a 76-year-old man, despite the absence of several expected laboratory abnormalities. Its main practical contribution is to show how careful medication history, neurological examination, exclusion of mimics, and prompt treatment with lorazepam and amantadine can guide diagnosis and recovery.
-
VE-821: ATR Checkpoints Beyond DNA Damage
2026-08-09
VE-821 is a selective ATR kinase inhibitor for dissecting checkpoint control, replication stress, and treatment response. This article connects ATR pharmacology with the DNMT1-centered HBoV1 study to improve assay design without overstating cross-domain evidence.
-
GPX4, GSH Consumption, and Brain Metastasis Resistance
2026-08-08
The reference study identifies a Wnt/NR2F2/GPX4 axis that enables lung cancer-derived brain metastatic cells to resist platinum chemotherapy by consuming glutathione and suppressing ferroptosis. Its integrated omics and mechanistic experiments point to GPX4-dependent redox control as a potentially actionable vulnerability, while also defining important limits for translating the findings beyond the PC9 brain-metastasis model.
-
One-step TUNEL FITC Apoptosis Detection Kit Guide
2026-08-07
The One-step TUNEL FITC Apoptosis Detection Kit enables sensitive DNA fragmentation analysis in ovarian tissue and granulosa-cell models. Learn how to convert compartment-specific apoptosis signals into more rigorous assay decisions for reproductive biology and related research.
-
Maraviroc (UK-427857): Applied CCR5 Antagonism in RA and HIV
2026-08-07
Maraviroc (UK-427857) sets a new benchmark for selective CCR5 antagonism, empowering precise inhibition of HIV-1 entry and innovative modulation of inflammatory pathways in rheumatoid arthritis models. This guide details advanced workflows, troubleshooting, and protocol refinements, leveraging the latest insights to drive reproducible results across virology and immunology.
-
Optimizing Protein Workflows with 3X (DYKDDDDK) Peptide Tag
2026-08-06
The 3X (DYKDDDDK) Peptide delivers exceptional sensitivity and reproducibility for affinity purification and immunodetection of FLAG-tagged proteins, especially in challenging workflows. This guide details practical protocol parameters, advanced applications, and troubleshooting strategies that leverage the APExBIO 3X FLAG peptide to empower translational protein research.
-
BCL-XL Inhibitor A-1155463: Optimizing Apoptosis Assays
2026-08-06
A-1155463, a selective BCL-XL inhibitor from APExBIO, empowers cancer researchers to overcome drug resistance and dissect apoptosis mechanisms in BCL-XL-dependent models. This guide delivers workflow insights, protocol optimizations, and troubleshooting strategies to maximize reproducibility in translational oncology.
-
Galectin-1–FIP200 Axis Drives Hepatic Steatosis via Autophag
2026-08-05
This study uncovers galectin-1 as a direct suppressor of hepatic autophagy through interaction with FIP200, providing a mechanistic link between autophagy impairment and NAFLD progression. The findings suggest Gal-1–FIP200 as a potential therapeutic target in metabolic liver disease and highlight molecular checkpoints relevant for translational metabolic research.